Antimicrobial peptides: A plausible approach for COVID-19 treatment

Expert Opin Drug Discov. 2022 May;17(5):473-487. doi: 10.1080/17460441.2022.2050693. Epub 2022 Mar 9.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19), which emerged as a major public health threat, has affected >400 million people globally leading to >5 million mortalities to date. Treatments of COVID-19 are still to be developed as the available therapeutic approaches are not able to combat the virus causing the disease (severe acute respiratory syndrome coronavirus-2; SARS-CoV-2) satisfactorily. However, antiviral peptides (AVPs) have demonstrated prophylactic and therapeutic effects against many coronaviruses (CoVs).

Areas covered: This review critically discusses various types of AVPs evaluated for the treatment of COVID-19 along with their mechanisms of action. Furthermore, the peptides inhibiting the entry of the virus by targeting its binding to angiotensin-converting enzyme 2 (ACE2) or integrins, fusion mechanism as well as activation of proteolytic enzymes (cathepsin L, transmembrane serine protease 2 (TMPRSS2), or furin) are also discussed.

Expert opinion: Although extensively investigated, successful treatment of COVID-19 is still a challenge due to emergence of virus mutants. Antiviral peptides are anticipated to be blockbuster drugs for the management of this serious infection because of their formulation and therapeutic advantages. Although they may act on different pathways, AVPs having a multi-targeted approach are considered to have the upper hand in the management of this infection.

Keywords: COVID-19; SARS-CoV-2; antivirals; coronavirus; peptides.

Publication types

  • Review

MeSH terms

  • Antimicrobial Peptides
  • Antiviral Agents / pharmacology
  • COVID-19 Drug Treatment*
  • Humans
  • SARS-CoV-2
  • Virus Internalization

Substances

  • Antimicrobial Peptides
  • Antiviral Agents